Major Estimate Revision • Apr 07
Consensus EPS estimates fall by 21% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥4.63b to CN¥4.39b. EPS estimate also fell from CN¥0.968 per share to CN¥0.768 per share. Net income forecast to grow 220% next year vs 17% growth forecast for Healthcare industry in Hong Kong. Consensus price target down from HK$19.05 to HK$18.61. Share price rose 8.2% to HK$12.35 over the past week. Reported Earnings • Mar 31
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.27 (down from CN¥0.95 in FY 2024). Revenue: CN¥4.01b (down 9.8% from FY 2024). Net income: CN¥164.5m (down 73% from FY 2024). Profit margin: 4.1% (down from 14% in FY 2024). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 61%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings. Bekanntmachung • Mar 30
Hygeia Healthcare Holdings Co., Limited, Annual General Meeting, Jun 26, 2026 Hygeia Healthcare Holdings Co., Limited, Annual General Meeting, Jun 26, 2026. Bekanntmachung • Mar 23
Hygeia Healthcare Holdings Co., Limited(SEHK:6078) dropped from FTSE All-World Index (USD) Hygeia Healthcare Holdings Co., Limited(SEHK:6078) dropped from FTSE All-World Index (USD) Bekanntmachung • Mar 18
Hygeia Healthcare Holdings Co., Limited to Report Fiscal Year 2025 Results on Mar 30, 2026 Hygeia Healthcare Holdings Co., Limited announced that they will report fiscal year 2025 results on Mar 30, 2026 Major Estimate Revision • Feb 09
Consensus EPS estimates fall by 19% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥4.31b to CN¥4.15b. EPS estimate also fell from CN¥0.885 per share to CN¥0.713 per share. Net income forecast to grow 15% next year vs 16% growth forecast for Healthcare industry in Hong Kong. Consensus price target down from HK$19.58 to HK$19.17. Share price rose 4.5% to HK$13.40 over the past week. Major Estimate Revision • Feb 04
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥4.33b to CN¥4.15b. EPS estimate also fell from CN¥0.898 per share to CN¥0.78 per share. Net income forecast to grow 20% next year vs 16% growth forecast for Healthcare industry in Hong Kong. Consensus price target down from HK$19.88 to HK$19.26. Share price was steady at HK$13.23 over the past week. Bekanntmachung • Jan 30
Hygeia Healthcare Holdings Co., Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025 Hygeia Healthcare Holdings Co., Limited provided unaudited consolidated earnings guidance for the year ended December 31, 2025. For the period, the company expects revenue of approximately RMB 4,000 million to RMB 4,050 million, representing a decrease of approximately 9% to 10% as compared to a year ago and net profit of approximately RMB 140 million to RMB 200 million, representing a decrease of approximately 66% to 76% as compared to a year ago. The decrease in revenue and net profit was primarily attributable to the impact of industry and macro-economic headwinds, as well as the impact of start-up costs and increased depreciation and amortization from newly opened hospitals of the Group. In addition to the aforementioned factors, the decrease in net profit of the Group was also primarily attributable to the provision for impairment of goodwill of Etern Group Ltd. In determining the necessity and amount for such impairment and provisions, the Company has carefully evaluated the Group's operating and financial performance as well as future prospects of its businesses. The actual amount of impairment and provisions remain subject to further assessment by the Company. Bekanntmachung • Dec 18
Hygeia Healthcare Holdings Co., Limited (SEHK:6078) commences an Equity Buyback Plan for 61,849,900 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2025. Hygeia Healthcare Holdings Co., Limited (SEHK:6078) commences share repurchases on December 17, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 27, 2025. As per the mandate, the company is authorized to repurchase up to 61,849,900 shares, representing 10% of its issued share capital. The purpose of repurchase program is to enhance the net assets and/or its earnings per share. The repurchases will be made out of the funds legally available for such purpose in accordance with the Articles of Association and the Cayman Companies Act. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of June 27, 2025, the company had 618,499,000 shares in issue.
On December 15, 2025, the company announced a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of its shares. Recent Insider Transactions • Sep 19
Chairman & Co-CEO recently bought HK$23m worth of stock On the 18th of September, Yiwen Zhu bought around 2m shares on-market at roughly HK$13.83 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yiwen has been a buyer over the last 12 months, purchasing a net total of HK$36m worth in shares. Major Estimate Revision • Sep 04
Consensus EPS estimates fall by 17% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥4.71b to CN¥4.42b. EPS estimate also fell from CN¥1.09 per share to CN¥0.904 per share. Net income forecast to grow 36% next year vs 24% growth forecast for Healthcare industry in Hong Kong. Consensus price target down from HK$21.56 to HK$20.75. Share price was steady at HK$14.39 over the past week. Reported Earnings • Aug 31
First half 2025 earnings released: EPS: CN¥0.40 (vs CN¥0.61 in 1H 2024) First half 2025 results: EPS: CN¥0.40 (down from CN¥0.61 in 1H 2024). Revenue: CN¥1.99b (down 17% from 1H 2024). Net income: CN¥247.1m (down 36% from 1H 2024). Profit margin: 12% (down from 16% in 1H 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Bekanntmachung • Aug 18
Hygeia Healthcare Holdings Co., Limited to Report First Half, 2025 Results on Aug 28, 2025 Hygeia Healthcare Holdings Co., Limited announced that they will report first half, 2025 results on Aug 28, 2025 Reported Earnings • Apr 30
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.95 (down from CN¥1.08 in FY 2023). Revenue: CN¥4.45b (up 9.1% from FY 2023). Net income: CN¥598.3m (down 12% from FY 2023). Profit margin: 14% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Apr 11
Chairman & Co-CEO recently bought HK$5.0m worth of stock On the 7th of April, Yiwen Zhu bought around 391k shares on-market at roughly HK$12.80 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yiwen has been a buyer over the last 12 months, purchasing a net total of HK$13m worth in shares. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Major Estimate Revision • Apr 03
Consensus revenue estimates fall by 19% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥6.03b to CN¥4.86b. EPS estimate fell from CN¥1.47 to CN¥1.12 per share. Net income forecast to grow 42% next year vs 33% growth forecast for Healthcare industry in Hong Kong. Consensus price target down from HK$28.38 to HK$26.70. Share price rose 2.5% to HK$14.80 over the past week. Recent Insider Transactions • Apr 01
Chairman & Co-CEO recently bought HK$5.0m worth of stock On the 28th of March, Yiwen Zhu bought around 357k shares on-market at roughly HK$14.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yiwen has been a buyer over the last 12 months, purchasing a net total of HK$19m worth in shares. Reported Earnings • Mar 28
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.95 (down from CN¥1.08 in FY 2023). Revenue: CN¥4.45b (up 9.1% from FY 2023). Net income: CN¥598.3m (down 12% from FY 2023). Profit margin: 14% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Bekanntmachung • Mar 28
Hygeia Healthcare Holdings Co., Limited, Annual General Meeting, Jun 27, 2025 Hygeia Healthcare Holdings Co., Limited, Annual General Meeting, Jun 27, 2025. Bekanntmachung • Mar 17
Hygeia Healthcare Holdings Co., Limited to Report Fiscal Year 2024 Results on Mar 27, 2025 Hygeia Healthcare Holdings Co., Limited announced that they will report fiscal year 2024 results on Mar 27, 2025 Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to HK$13.48, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 10x in the Healthcare industry in Hong Kong. Total loss to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to HK$17.90, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 10x in the Healthcare industry in Hong Kong. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$33.00 per share. New Risk • Nov 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Oct 03
Investor sentiment improves as stock rises 34% After last week's 34% share price gain to HK$23.70, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Healthcare industry in Hong Kong. Total loss to shareholders of 63% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to HK$16.00, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 7x in the Healthcare industry in Hong Kong. Total loss to shareholders of 74% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$10.00 per share. Reported Earnings • Aug 30
First half 2024 earnings released: EPS: CN¥0.61 (vs CN¥0.53 in 1H 2023) First half 2024 results: EPS: CN¥0.61 (up from CN¥0.53 in 1H 2023). Revenue: CN¥2.38b (up 35% from 1H 2023). Net income: CN¥384.6m (up 15% from 1H 2023). Profit margin: 16% (down from 19% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Bekanntmachung • Aug 20
Hygeia Healthcare Holdings Co., Limited to Report First Half, 2024 Results on Aug 29, 2024 Hygeia Healthcare Holdings Co., Limited announced that they will report first half, 2024 results on Aug 29, 2024 Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to HK$23.05, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 8x in the Healthcare industry in Hong Kong. Total loss to shareholders of 71% over the past three years. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to HK$37.00, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 9x in the Healthcare industry in Hong Kong. Total loss to shareholders of 40% over the past three years. Reported Earnings • Apr 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥1.08 (up from CN¥0.77 in FY 2022). Revenue: CN¥4.08b (up 28% from FY 2022). Net income: CN¥682.9m (up 43% from FY 2022). Profit margin: 17% (up from 15% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 7.5%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Apr 06
Chairman & Co-CEO recently bought HK$13m worth of stock On the 3rd of April, Yiwen Zhu bought around 440k shares on-market at roughly HK$29.54 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yiwen has been a buyer over the last 12 months, purchasing a net total of HK$69m worth in shares. Bekanntmachung • Mar 27
Hygeia Healthcare Holdings Co., Limited, Annual General Meeting, Jun 28, 2024 Hygeia Healthcare Holdings Co., Limited, Annual General Meeting, Jun 28, 2024. Reported Earnings • Mar 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥1.08 (up from CN¥0.77 in FY 2022). Revenue: CN¥4.08b (up 28% from FY 2022). Net income: CN¥682.9m (up 43% from FY 2022). Profit margin: 17% (up from 15% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 7.5%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Bekanntmachung • Mar 14
Hygeia Healthcare Holdings Co., Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Hygeia Healthcare Holdings Co., Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$27.30, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Healthcare industry in Hong Kong. Total loss to shareholders of 61% over the past three years. Recent Insider Transactions • Jan 12
Chairman & Co-CEO recently bought HK$4.1m worth of stock On the 10th of January, Yiwen Zhu bought around 133k shares on-market at roughly HK$30.67 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$20m. Yiwen has been a buyer over the last 12 months, purchasing a net total of HK$38m worth in shares. Recent Insider Transactions • Dec 20
Chairman & Co-CEO recently bought HK$20m worth of stock On the 12th of December, Yiwen Zhu bought around 547k shares on-market at roughly HK$36.59 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yiwen has been a buyer over the last 12 months, purchasing a net total of HK$29m worth in shares. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to HK$33.40, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Healthcare industry in Hong Kong. Total loss to shareholders of 30% over the past three years. Recent Insider Transactions • Sep 06
Chairman & Co-CEO recently bought HK$9.0m worth of stock On the 31st of August, Yiwen Zhu bought around 229k shares on-market at roughly HK$39.21 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Yiwen's only on-market trade for the last 12 months. Reported Earnings • Aug 30
First half 2023 earnings released: EPS: CN¥0.53 (vs CN¥0.36 in 1H 2022) First half 2023 results: EPS: CN¥0.53 (up from CN¥0.36 in 1H 2022). Revenue: CN¥1.76b (up 15% from 1H 2022). Net income: CN¥334.1m (up 49% from 1H 2022). Profit margin: 19% (up from 15% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Bekanntmachung • Aug 18
Hygeia Healthcare Holdings Co., Limited to Report First Half, 2023 Results on Aug 29, 2023 Hygeia Healthcare Holdings Co., Limited announced that they will report first half, 2023 results on Aug 29, 2023 Bekanntmachung • Jul 27
Hygeia Healthcare Holdings Co., Limited (SEHK:6078) entered into the acquisition agreement to acquire Datang International (Hong Kong) Limited for CNY 1.2 billion. Hygeia Healthcare Holdings Co., Limited (SEHK:6078) entered into the acquisition agreement to acquire Datang International (Hong Kong) Limited for CNY 1.2 billion on July 25, 2023. As part of the transaction, Hygeia Healthcare will pay a consideration of CNY 1,162 million to Datang International. The total consideration is subject to downward adjustment (if any) by deducting from the Consideration the net liabilities (including such provisions made for net liabilities as agreed by the parties). Datang International holds 70% equity interest in Chang’an Hospital Co., Ltd. In a related transaction, Hygeia Hospital Management conditionally agreed to acquire 30% equity interest in Chang’an Hospital Co., Ltd. at a consideration of CNY 498 million. As a result, Chang’an Hospital Co., Ltd. will become an indirect wholly-owned subsidiary of Hygeia Healthcare. In the agreement terminated by Hygeia Healthcare, then Hygeia Healthcare will pay a CNY 60 million as a termination fee to Datang International and the agreement terminated by Datang International, then Datang International will have to pay a CNY60 million as a termination fee to Hygeia Healthcare. The transaction is subject to anti-trust declaration of concentration of undertakings to the State Administration for Market Regulation in respect of the acquisition and approval of director and shareholders of Datang International. Jingtian & Gongcheng acted as legal advisor to Hygeia Healthcare. Buying Opportunity • Jul 06
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 30%. The fair value is estimated to be HK$54.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 52%. For the next 3 years, revenue is forecast to grow by 23% per annum. Earnings is also forecast to grow by 30% per annum over the same time period. Upcoming Dividend • Jun 23
Upcoming dividend of CN¥0.15 per share at 0.4% yield Eligible shareholders must have bought the stock before 30 June 2023. Payment date: 27 July 2023. Trailing yield: 0.4%. Lower than top quartile of Hong Kong dividend payers (7.8%). Lower than average of industry peers (2.9%). Reported Earnings • Mar 21
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.77 (up from CN¥0.71 in FY 2021). Revenue: CN¥3.20b (up 38% from FY 2021). Net income: CN¥476.8m (up 8.0% from FY 2021). Profit margin: 15% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in Hong Kong. Bekanntmachung • Jan 12
Hygeia Healthcare Holdings Co., Limited has completed a Follow-on Equity Offering in the amount of HKD 791.8 million. Hygeia Healthcare Holdings Co., Limited has completed a Follow-on Equity Offering in the amount of HKD 791.8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 14,800,000
Price\Range: HKD 53.5
Discount Per Security: HKD 0.321
Transaction Features: Subsequent Direct Listing Buying Opportunity • Nov 23
Now 20% undervalued Over the last 90 days, the stock is up 2.3%. The fair value is estimated to be HK$54.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 28%. Revenue is forecast to grow by 60% in 2 years. Earnings is forecast to grow by 93% in the next 2 years. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Chun Zhao was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buying Opportunity • Nov 08
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 3.2%. The fair value is estimated to be HK$54.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 28%. Revenue is forecast to grow by 60% in 2 years. Earnings is forecast to grow by 94% in the next 2 years. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improved over the past week After last week's 17% share price gain to HK$43.80, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 12x in the Healthcare industry in Hong Kong. Total loss to shareholders of 31% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$54.70 per share. Valuation Update With 7 Day Price Move • Oct 24
Investor sentiment deteriorated over the past week After last week's 20% share price decline to HK$36.10, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 14x in the Healthcare industry in Hong Kong. Total loss to shareholders of 50% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$60.77 per share. Reported Earnings • Oct 01
First half 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.32 in 1H 2021) First half 2022 results: EPS: CN¥0.36 (up from CN¥0.32 in 1H 2021). Revenue: CN¥1.53b (up 64% from 1H 2021). Net income: CN¥224.2m (up 14% from 1H 2021). Profit margin: 15% (down from 21% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare industry in Hong Kong. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment improved over the past week After last week's 15% share price gain to HK$49.60, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 15x in the Healthcare industry in Hong Kong. Total loss to shareholders of 15% over the past year. Reported Earnings • Sep 01
First half 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.32 in 1H 2021) First half 2022 results: EPS: CN¥0.36 (up from CN¥0.32 in 1H 2021). Revenue: CN¥1.53b (up 64% from 1H 2021). Net income: CN¥224.2m (up 14% from 1H 2021). Profit margin: 15% (down from 21% in 1H 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 28%, compared to a 33% growth forecast for the Healthcare industry in Hong Kong. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 19% share price gain to HK$43.55, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 13x in the Healthcare industry in Hong Kong. Total loss to shareholders of 52% over the past year. Reported Earnings • Apr 30
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.71 (up from CN¥0.38 in FY 2020). Revenue: CN¥2.32b (up 65% from FY 2020). Net income: CN¥441.5m (up 160% from FY 2020). Profit margin: 19% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 43%, compared to a 32% growth forecast for the industry in Hong Kong. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Kevin Chen was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Mar 31
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.71 (up from CN¥0.38 in FY 2020). Revenue: CN¥2.32b (up 65% from FY 2020). Net income: CN¥441.5m (up 160% from FY 2020). Profit margin: 19% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 39%, compared to a 37% growth forecast for the industry in Hong Kong. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment deteriorated over the past week After last week's 30% share price decline to HK$28.90, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 11x in the Healthcare industry in Hong Kong. Total loss to shareholders of 38% over the past year. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment improved over the past week After last week's 19% share price gain to HK$39.70, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 13x in the Healthcare industry in Hong Kong. Total loss to shareholders of 43% over the past year. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 17% share price decline to HK$38.90, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 15x in the Healthcare industry in Hong Kong. Total loss to shareholders of 45% over the past year.